Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer

Small molecule BET bromodomain inhibitors (BETi) are actively being pursued in clinical trials for the treatment of a variety of cancers, however, the mechanisms of resistance to BETi remain poorly understood. Using a mass spectrometry approach that globally measures kinase signaling at the proteomi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Rep
Main Authors: Kurimchak, Alison M., Shelton, Claude, Duncan, Kelly E., Johnson, Katherine J., Brown, Jennifer, O’Brien, Shane, Gabbasov, Rashid, Fink, Lauren S., Li, Yuesheng, Lounsbury, Nicole, Abou-Gharbia, Magid, Childers, Wayne E., Connolly, Denise C., Chernoff, Jonathan, Peterson, Jeffrey R., Duncan, James S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4972668/
https://ncbi.nlm.nih.gov/pubmed/27452461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2016.06.091
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados